<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04539665</url>
  </required_header>
  <id_info>
    <org_study_id>crohn's mesentery</org_study_id>
    <nct_id>NCT04539665</nct_id>
  </id_info>
  <brief_title>Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease.</brief_title>
  <official_title>Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease: A Multicenter Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montreal General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jewish General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Montreal General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is looking at the role of the mesentery in disease recurrence for ileocolic Crohn's&#xD;
      disease. It is a prospective study that has been designed to perform extended mesenteric&#xD;
      excision on patients undergoing their first ileocolic resection for Crohn's disease.&#xD;
      Endoscopic recurrence will be monitored with the hypothesis that patients receiving extended&#xD;
      mesenteric ileocolic resection will have reduced endoscopic recurrence at 6 months after&#xD;
      resection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current standard of care for ileocolic Crohn's disease (CD) is a limited mesenteric&#xD;
      resection. There is growing, but still limited, evidence that extended mesenteric excision&#xD;
      during ileocolic resection is beneficial in decreasing disease recurrence. We propose a&#xD;
      prospective multicenter cohort study to better understand the role of extended mesenteric&#xD;
      excision in ileocolic CD and how it affects disease recurrence. The primary outcome of this&#xD;
      study will be the rate of endoscopic recurrence at 6 months in patients undergoing first-time&#xD;
      resection for ileocolic CD. Secondary outcomes will include endoscopic recurrence at 18&#xD;
      months and rates of recurrence requiring surgery by 2 years. These outcomes will be compared&#xD;
      to historical controls (limited mesenteric resection). Our hypothesis is that patients&#xD;
      receiving extended mesenteric ileocolic resection will have reduced endoscopic recurrence at&#xD;
      6 months after resection. As seen in previous studies, advanced mesenteric and mucosal&#xD;
      disease predicts increased surgical recurrence.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with endoscopic recurrence at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Endoscopic recurrence after extended mesenteric ileocolic resection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with endoscopic recurrence at 18 months</measure>
    <time_frame>18 months</time_frame>
    <description>Endoscopic recurrence after extended mesenteric ileocolic resection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of recurrence requiring surgery by 2 years</measure>
    <time_frame>24 months</time_frame>
    <description>Surgical recurrence after extended mesenteric ileocolic resection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of post-operative complications compared between study groups</measure>
    <time_frame>30 days</time_frame>
    <description>Post-operative complications including: wound infections, anastomotic leak, intra-abdominal abscess, venous-thromboembolic complications, and primary ileus within 30 days of the first resection.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Crohn Disease</condition>
  <condition>Recurrence</condition>
  <condition>Crohn's Ileocolitis</condition>
  <arm_group>
    <arm_group_label>Intervention Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prospective study arm involving an extended mesenteric ileocolic excision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Historical controls from a retrospective chart review of patients who had a limited ileocolic resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Extended mesenteric resection.</intervention_name>
    <description>Patients will undergo an ileocolic resection involving high ligation of the ileocolic pedicle, complete mobilization of the mesentery off of the retroperitoneum, and resection of the entire mesentery related to the specimen.</description>
    <arm_group_label>Intervention Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adults &gt;18 years old&#xD;
&#xD;
          -  diagnosis of CD limited to the distal ileum/ileocolic region&#xD;
&#xD;
          -  no previous ileocolic resection&#xD;
&#xD;
          -  all forms of CD presentation will be included - stricturing, fistulizing, perforating&#xD;
             etc.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous ileocolic resection&#xD;
&#xD;
          -  other sites of CD&#xD;
&#xD;
          -  intraabdominal sepsis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sender Liberman, MD</last_name>
    <phone>(514) 934-8486</phone>
    <email>sender.liberman@mcgill.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marylise Boutros, MD</last_name>
    <phone>(514) 340-8222</phone>
    <phone_ext>28400</phone_ext>
    <email>maryliseboutros@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Montreal General Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sender Liberman, MD</last_name>
      <phone>(514) 934-8486</phone>
      <email>sender.liberman@mcgill.ca</email>
    </contact>
    <contact_backup>
      <last_name>Bessissow Talat, MD</last_name>
      <phone>(514) 934-8309</phone>
      <email>talat.bessissow@mcgill.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marylise Boutros, MD</last_name>
      <phone>(514) 340-8222</phone>
      <phone_ext>28400</phone_ext>
      <email>marylise.boutros@mcgill.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>September 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2020</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montreal General Hospital</investigator_affiliation>
    <investigator_full_name>Sender Liberman MD</investigator_full_name>
    <investigator_title>Dr. Sender Liberman, Associate Professor of Surgery and Oncology (McGill University), PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

